Jason Christopher Rech

USPTO Granted Patents = 21 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 5.7

ph-index = 7

Forward Citations = 181(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2020)
Ann Arbor, MI (US) (2019 - 2024)

Company Filing History:

19 out of 2,076

Janssen Pharmaceutica Nv

patents

2 out of 3,370

University of Michigan

patents

Years Active: 2012-2025

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12338243 - P2X7 modulators (2025-06-24),

2. 11999731 - EGFR dimer disruptors and use of the same (2024-06-04),

3. 11759455 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators (2023-09-19),

4. 11358965 - EGFR dimer disruptors and use of the same (2022-06-14),

5. 11207298 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators (2021-12-28),

6. 10766880 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2020-09-08),

7. 10617676 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators (2020-04-14),

8. 10377753 - Substituted 4-azaindoles and their use as GluN2B receptor modulators (2019-08-13),

9. 10233173 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2019-03-19),

10. 10150766 - P2X7 modulators (2018-12-11),

11. 10112937 - P2X7 modulators and methods of use (2018-10-30),

12. 10071988 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2018-09-11),

13. 10053463 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators (2018-08-21),

14. 10047092 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators (2018-08-14),

15. 9963447 - Substituted 4-azaindoles and their use as GluN2B receptor modulators (2018-05-08),

As your AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I will produce the requested article on inventor Jason Christopher Rech.

Title: Unveiling the Inventive Journey of Jason Christopher Rech

Introduction:

Jason Christopher Rech, a prolific inventor based in San Diego, CA, has left an indelible mark in the field of pharmaceuticals and medical sciences. With an impressive portfolio of 19 patents, his innovative spirit continues to drive advancements in the sector.

Latest Patents:

Rech's latest patents showcase his expertise in developing novel compounds with significant therapeutic potential. One such patent is on "Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones," acting as GLUN2B receptor modulators, which hold promise in treating diseases mediated by NR2B receptor activity. Another notable patent involves "EGFR dimer disruptors," crucial in the treatment of cancer by targeting EGFR modulation.

Career Highlights:

Over the course of his career, Rech has made significant contributions while working at esteemed institutions. His tenure at Janssen Pharmaceutica Nv and the University of Michigan has been marked by groundbreaking innovations that have pushed the boundaries of pharmaceutical research.

Collaborations:

In his quest for innovation, Rech has collaborated with top-notch professionals in the field. Close associates like Jessica L Wall and Michael Anthony Letavic have been instrumental in shaping his innovative ideas into tangible inventions, fostering a culture of excellence and collaboration.

Conclusion:

Jason Christopher Rech's journey as an inventor exemplifies the relentless pursuit of innovation in the realm of pharmaceuticals. His patents not only underscore his scientific acumen but also symbolize his commitment to advancing healthcare through groundbreaking discoveries. With a trailblazing career and a penchant for collaboration, Rech stands as a beacon of innovation in the landscape of inventions and patents.

This text is generated by artificial intelligence and may not be accurate.